ReviewMicroorganisms2021
Review in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- Secretome Profiling ofAntibiotics (Basel, Switzerland) · 2026Article
- Advances and prospects of mucosal vaccination in the prevention and control of avian influenza.Frontiers in immunology · 2026Review
- Enhancing Resistance toNutrients · 2025Article
- Encapsulation of a Probiotic Bacterial Strain in a Biocompatible Iron(III) Fumarate Matrix.ACS applied bio materials · 2025Article
- The Immunomodulatory Effects and Applications of Probiotic Lactiplantibacillus plantarum in Vaccine Development.Probiotics and antimicrobial proteins · 2024Review
- Antagonistic Effects ofMicroorganisms · 2024Article
- ImmunobioticInternational journal of molecular sciences · 2023Article
- The potential use of bacteria and bacterial derivatives as drug delivery systems for viral infection.Virology journal · 2023Review
- Illuminating the Genomic Landscape ofMicroorganisms · 2023Article
- Mucosal immunization with lactiplantibacillus plantarum-displaying recombinant SARS-CoV-2 epitopes on the surface induces humoral and mucosal immune responses in mice.Microbial cell factories · 2023Article
- The Respiratory Commensal BacteriumVaccines · 2023Article
- Article
- The Mucus Binding Factor Is Not Necessary forInternational journal of molecular sciences · 2022Article
- Immunomodulatory Effects of Probiotics: A Novel Preventive Approach for the Control of Bovine Mastitis.Microorganisms · 2022Review
- The Ability of Postimmunobiotics fromMicroorganisms · 2022Article
- Article
- Article
- Article
- Article
- Microbiota and the Response to Vaccines Against Respiratory Virus.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
Abstract
The most important characteristics regarding the mucosal infection and immune responses against the Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) as well as the current vaccines against coronavirus disease 2019 (COVID-19) in development or use are revised to emphasize the opportunity for lactic acid bacteria (LAB)-based vaccines to offer a valid alternative in the fight against this disease. In addition, this article revises the knowledge on: (a) the cellular and molecular mechanisms involved in the improvement of mucosal antiviral defenses by beneficial
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.